Niagen Bioscience (NAGE)

Overall impact
C (48)

Commentary

Niagen Bioscience is an average overall performer. With a 'C' rating of 47.5 for overall impact (37th percentile compared to all companies), Niagen Bioscience ranks 634th out of 655 industry peers, behind Eurofins Scientific, Curium Pharma, Allena Pharmaceuticals and 630 others, and ahead of Apellis Pharmaceuticals, SpringWorks Therapeutics, PLx Pharma and 18 others. On top material causes for Niagen Bioscience's industry (Biotechnology), Niagen Bioscience performs well in Child and Maternal Health (95.3 score), Child and Maternal Health (95.3), Child and Maternal Health (95.3) and 3 other causes where it received an 'A' score and performs poorly in Disaster Readiness and Effective Aid (16.2 score), Reduced Waste (13.7), Racial Justice and Civil Rights (0.1) and 7 other causes where it received a 'D' or 'F' score.
Impact
Cause NAGE
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
117
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ca, United States
Share classes
NAGE
Description
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Material causes
Ethos considers the following causes material for Niagen Bioscience, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.